RELMADA THERAPEUTICS, INC. Long-term Line of Credit
RELMADA THERAPEUTICS, INC. (RLMD) had Long-term Line of Credit of $0 as of 2017-06-30, per its 10-K filed 2017-09-28.
Discontinued › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:LineOfCredit · last filed 2017-09-28
- 2017-06-30: Long-term Line of Credit $0.00.
- 2017-03-31: Long-term Line of Credit $392.60K.
- 2016-12-31: Long-term Line of Credit $392.60K.
- 2016-09-30: Long-term Line of Credit $392.60K.
| Period end | Long-term Line of Credit |
|---|---|
| 2017-06-30 | $0.00 10-K · filed 2017-09-28 |
| 2017-03-31 | $392.60K 10-Q · filed 2017-05-15 |
| 2016-12-31 | $392.60K 10-Q · filed 2017-02-10 |
| 2016-09-30 | $392.60K 10-Q · filed 2016-11-10 |
| 2016-06-30 | $390.80K 10-K · filed 2017-09-28 |
| 2015-06-30 | $390.80K 10-K · filed 2015-09-11 |
| 2012-04-30 | $975.00K 10-KT · filed 2014-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |